{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-24-000146","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.125935+00:00","generated_at":"2026-05-31T15:33:23.183921+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Q2 net loss $445M; revs up 9% to $1.04B; Jakafi guidance raised; $2B buyback completed","bullets":["Total revenues $1,044M (+9% YoY); Jakafi $706M (+3%), Opzelura $122M (+52%).","GAAP net loss $444.6M vs $203.5M income in Q2 2023; non-GAAP net loss $396.1M.","Completed $2.0B share repurchase (33.3M shares at $60 each) in June 2024.","Raised low end of 2024 Jakafi revenue guidance to $2,710-$2,750M; revised R&D guidance up.","Discontinued development of oral PD-L1, LAG-3, TIM-3, LAG-3xPD-1; focus on high-impact programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-24-000146","json":"https://secwatch.observer/filing/0000879169-24-000146.json","markdown":"https://secwatch.observer/filing/0000879169-24-000146.md","text":"https://secwatch.observer/filing/0000879169-24-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000146/0000879169-24-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916924000146/incy-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:33:23.183921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}